ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 245 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $893,298,514 | -13.0% | 42,864,612 | 0.0% | 5.15% | -13.3% |
Q2 2023 | $1,026,607,457 | +30.1% | 42,864,612 | +2.2% | 5.94% | +38.4% |
Q1 2023 | $789,282,307 | +18.3% | 41,938,486 | +0.0% | 4.29% | +7.1% |
Q4 2022 | $667,421,897 | -2.7% | 41,923,486 | 0.0% | 4.01% | -10.8% |
Q3 2022 | $685,868,000 | +16.1% | 41,923,486 | 0.0% | 4.49% | +34.0% |
Q2 2022 | $590,702,000 | -41.8% | 41,923,486 | +0.0% | 3.35% | -42.6% |
Q1 2022 | $1,015,077,000 | +3.8% | 41,910,704 | 0.0% | 5.83% | +22.6% |
Q4 2021 | $978,196,000 | +40.5% | 41,910,704 | 0.0% | 4.76% | +55.7% |
Q3 2021 | $696,137,000 | -31.9% | 41,910,704 | 0.0% | 3.06% | -31.9% |
Q2 2021 | $1,022,202,000 | -5.5% | 41,910,704 | 0.0% | 4.49% | -4.2% |
Q1 2021 | $1,081,296,000 | -51.7% | 41,910,704 | +0.0% | 4.69% | -44.5% |
Q4 2020 | $2,240,219,000 | +29.6% | 41,904,586 | 0.0% | 8.44% | +22.2% |
Q3 2020 | $1,728,564,000 | -14.9% | 41,904,586 | 0.0% | 6.91% | -22.9% |
Q2 2020 | $2,031,115,000 | +14.7% | 41,904,586 | 0.0% | 8.96% | -17.8% |
Q1 2020 | $1,770,469,000 | +1.3% | 41,904,586 | +2.6% | 10.90% | +17.3% |
Q4 2019 | $1,747,759,000 | +18.9% | 40,854,586 | 0.0% | 9.29% | -7.1% |
Q3 2019 | $1,470,357,000 | +40.0% | 40,854,586 | +4.0% | 10.00% | +40.1% |
Q2 2019 | $1,050,277,000 | -1.5% | 39,292,086 | -1.1% | 7.14% | +4.6% |
Q1 2019 | $1,066,317,000 | +66.0% | 39,713,842 | 0.0% | 6.83% | +29.8% |
Q4 2018 | $642,173,000 | +8.8% | 39,713,842 | +39.6% | 5.26% | +35.2% |
Q3 2018 | $590,396,000 | +42.0% | 28,439,114 | +4.4% | 3.89% | +24.5% |
Q2 2018 | $415,777,000 | -32.0% | 27,228,338 | 0.0% | 3.12% | -39.8% |
Q1 2018 | $611,821,000 | -25.4% | 27,228,338 | 0.0% | 5.19% | -27.0% |
Q4 2017 | $819,845,000 | -15.7% | 27,228,338 | +5.5% | 7.11% | -9.9% |
Q3 2017 | $972,631,000 | +35.1% | 25,819,768 | 0.0% | 7.89% | +25.3% |
Q2 2017 | $720,113,000 | -18.9% | 25,819,768 | 0.0% | 6.30% | -13.3% |
Q1 2017 | $887,684,000 | +19.2% | 25,819,768 | 0.0% | 7.26% | -0.5% |
Q4 2016 | $744,642,000 | -9.3% | 25,819,768 | 0.0% | 7.30% | -2.1% |
Q3 2016 | $821,327,000 | +3.2% | 25,819,768 | +5.3% | 7.45% | -10.7% |
Q2 2016 | $795,813,000 | +17.5% | 24,516,738 | +1.3% | 8.34% | +16.9% |
Q1 2016 | $677,019,000 | -7.3% | 24,213,838 | +18.2% | 7.14% | +18.0% |
Q4 2015 | $730,163,000 | +7.8% | 20,481,442 | 0.0% | 6.05% | -3.3% |
Q3 2015 | $677,321,000 | -21.0% | 20,481,442 | 0.0% | 6.26% | -16.8% |
Q2 2015 | $857,763,000 | +28.5% | 20,481,442 | 0.0% | 7.52% | +35.5% |
Q1 2015 | $667,490,000 | +2.6% | 20,481,442 | 0.0% | 5.55% | -16.3% |
Q4 2014 | $650,286,000 | +28.2% | 20,481,442 | 0.0% | 6.64% | +3.9% |
Q3 2014 | $507,121,000 | +9.6% | 20,481,442 | 0.0% | 6.39% | +12.7% |
Q2 2014 | $462,676,000 | -7.2% | 20,481,442 | 0.0% | 5.67% | -10.5% |
Q1 2014 | $498,313,000 | -0.1% | 20,481,442 | +2.6% | 6.33% | -9.9% |
Q4 2013 | $498,679,000 | -9.0% | 19,955,126 | 0.0% | 7.03% | -9.8% |
Q3 2013 | $548,167,000 | +51.3% | 19,955,126 | 0.0% | 7.79% | +8.8% |
Q2 2013 | $362,186,000 | – | 19,955,126 | – | 7.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |